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Abstract
Introduction—Factor IX:C (FIX:C) levels vary in hemophilia B carriers even in pedigrees with a 
unifying genetic defect. Analyzing the balance between pro-and anticoagulants might increase our 
understanding of carriers’ bleeding potential.
Aim—In this research study, we evaluated bleeding scores (BS) and a novel mathematical model 
of thrombin generation (TG) in Amish FIX:C deficient carriers and controls.
Methods—Blood samples and BS were obtained from post-menarchal females, including 59 
carriers and 57 controls from the same extended pedigree. Factors II, V, VII, VIII, IX, X, 
antithrombin, tissue factor pathway inhibitor and protein C were assayed to generate mathematical 
models of TG in response to 5pM tissue factor (TF) and for TF + thrombomodulin. BS was based 
on a modification of the MCMDM-1VWD scoring system.
Results—Carriers had a lower mean FIX:C (68% vs. 119%), von Willebrand factor antigen (108 
vs.133) and Tissue activatable fibrinolysis inhibitor (103 vs. 111) compared to controls; both 
groups had a similar mean BS. Carriers demonstrated significantly lower TG parameters on both 
mathematical models compared to controls. Carriers with FIX:C ≤ 50% had lower TG curves than 
those > 50% but similar BS.
Conclusion—Thrombin generation showed significant differences between carriers and controls, 
between low (≤50%) and high (> 50%) FIX:C carriers, and specifically in the TF + 
thrombomodulin model, between high FIX:C carriers and controls, although the BS were not 
different.
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1. Introduction
Hemophilia B (HB) is an X-linked bleeding disorder resulting in a deficiency of FIX:C. 
Variable FIX:C levels can be seen in carriers within the same pedigree with a unifying 
mutation [1]. This variation has been attributed to differences in lyonization although there 
are other possible modifying factors [2–6]. FIX:C level has been utilized to predict bleeding 
risk and for dictating replacement therapy in both affected HB individuals and carriers; 
however FIX:C levels in carriers may not have a linear relationship to bleeding risk [7]. 
Some carriers with normal levels > 50% have increased bleeding tendency [8]. Quantitative 
assessment of bleeding symptoms can be performed with the use of bleeding scores [9–11]. 
The bleeding phenotype may be a cumulative effect of several variables of which FIX:C 
activity, mutation, age, stressors experienced as well as other circulating hemostatic 
parameters likely play an important role. Thrombin generation potential reflects the 
interplay between the procoagulant and anticoagulant proteins and may be an important 
predictor of bleeding phenotype in bleeding disorders [12]. However, these data have been 
inconsistent across carrier studies [13]. As thrombin is a key enzyme in hemostatic processes 
[14–16], aberrant thrombin formation can affect the critical balance of these processes 
yielding inappropriate bleeding or clotting [17–21]. Decades of research describing the 
reaction network of thrombin generation have enabled the creation of computational models 
of thrombin generation that are increasingly being used to understand normal hemostasis as 
well as coagulopathies by identifying underlying mechanisms, accelerating hypothesis 
testing, and simulating therapeutic interventions. In these models, initial concentrations of 
reactants will direct outcomes (i.e. thrombin generation) and thus, to the extent that 
individuals vary in the concentrations of coagulation components, their responses to a given 
hemostatic challenge will vary. Several groups have used patient factor level profiles to 
simulate thrombin generation using various models of the coagulation network in trauma 
[22], HIV and mortality [23], stroke [24], the effects of acidosis [25], and dilutional 
coagulopathy [26]. In principle, coagulation factor protein levels reflect the sum of 
developmental, environmental, genetic, nutritional, infectious agent, and pharmacological 
influences on the liver and other organs that regulate their synthesis and turnover [27]. Thus, 
computational models of the coagulation system that incorporate individual specific 
composition data are in principle linking the overall health of the individual and their 
hemostatic potential.
This research study is the first to evaluate mathematical models of thrombin generation and 
bleeding scores in a cohort of HB carriers with a unifying genetic mutation vs. an unaffected 
group from the same population.
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2. Methods
2.1. Study design, study setting and patient population
The study was conducted by Indiana Hemophilia & Thrombosis Center (IHTC), the Centers 
for Disease Control and Prevention (CDC), and the University of Vermont from 2008 to 
2013. Three populations were studied in this analysis – Amish FIX:C deficient carriers, 
Amish controls and non-Amish controls (NAC). The NAC samples were purchased 
commercially. The IHTC enrolled 170 female Amish individuals aged 1–75 years, including 
102 HB carriers and 68 controls from the same extended pedigree. All enrolled individuals 
or their guardians signed an IRB-approved informed consent or assent based upon age. HB 
carriers included obligate carriers or were individually genotyped and had the c.1025C > T; 
p.Thr342Met mutation, which is associated with moderate HB [1]. Amish unaffected 
controls were recruited by testing family members of the affected who were not at risk and 
those who had negative carrier testing results. Due to limited resources and difficulty in 
recruiting, the controls were not age matched but did belong to the same extended pedigree 
and were found not to have the familial F9 mutation, c.1025C > T. As the bleeding score is 
based on symptoms in two categories relevant only to post-pubertal women, post-partum 
hemorrhage (PPH) and menstrual bleeding, the final analysis was performed on post-
menarchal females only, reducing the analyzable numbers to 59 carriers and 57 controls. The 
Amish studied represent a unifying mutation and limited genetic pool; therefore to ensure 
that other inheritable factors which could potentially impact coagulation did not affect the 
TG results, we also included 15 samples of fresh frozen plasma from healthy female non 
Amish controls (NAC; age = 33 ± 9, range 21–51) purchased from Innovative Research 
(Novi, MI).
2.2. Bleeding score (BS)
BS was calculated for each participant using an in-house developed bleeding questionnaire 
based on the MCMDM-1 scoring system [28]. The questionnaire (Supplement 1, S1) was 
administered by trained research personnel to each subject, requiring an average of 15–25 
min for completion. The 8 categories queried included bruising, epistaxis, bleeding from 
minor wounds, post-partum hemorrhage (PPH), menorrhagia, bleeding post dental work, 
surgical bleeding and hemarthrosis; scoring for each bleeding symptom was 0 to +3, with an 
increasing score based on severity and need for medical care/intervention; maximum 
achievable total BS was 24 (Supplement 2, S2, Table S1). The bleeding phenotype of the 
Amish carriers has been reported previously, using a BS graded using only 7 bleeding 
symptoms [1]. For this study, carriers and controls were rescored with new category 
descriptions using all 8 bleeding symptoms, including bleeding from minor cuts and 
wounds.
2.2.1. Blood collection—Blood samples were drawn into 3.2% sodium citrate tubes 
and centrifuged within 2 h of sample collection; platelet-poor plasma was immediately 
frozen at −70 °C and thawed as needed for assay. Mutation analysis was performed on blood 
collected into EDTA tubes, as previously described [1].
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2.2.2. Measurement of procoagulants and anticoagulants—Procoagulant factors 
(F) II, V, VII, VIII, IX, X, XI, and XII activities were assayed by one-stage methods using 
appropriate factor-deficient plasmas (Precision Biologic, Dartmouth, Nova Scotia, Canada) 
and STA PTT-A (Diagnostica Stago, Parsippany, NJ, USA) or STA Neoplastin CI Plus 
(Diagnostica Stago). Fibrinogen was measured by Clauss method, STA-Fibrinogen 
(Diagnostica Stago, Parsippany, NJ, USA). VWF:Ag was measured using latex bead 
immunoassay (LIATest, Diagnostica Stago). Thrombin activatable fibrinolysis inhibitor 
(TAFI) was measured using a chromogenic substrate method (Pefakit TAFI, Pentapharm 
Ltd., Basel).
2.2.2.1. Anticoagulant factors: Antithrombin (AT) was measured by chromogenic assay 
(Stachrom AT III; Diagnostica Stago). Protein C (PC) was measured by clotting assay 
(Staclot C, Diagnostica Stago). Tissue factor pathway inhibitor (TFPI) was measured using 
ELISA (Diagnostica Stago).
All factors were expressed as percentages of the mean values in the healthy population. All 
assays were performed on STA-R Evolution (Diagnostica Stago, Parsipanny, NJ, USA).
Select factor levels (II, V, VII, VIII, IX, X, AT, PC and TFPI) were measured as described 
above on plasma of the 15 non-Amish controls. FXII and FXI were not measured in this 
subset as our mathematical model is based on tissue factor (TF) pathway of coagulation and 
hence measurements of these factors is not needed to run computational models of TF 
initiated thrombin generation. (Supplement 3, S3, Table S2).
Reference ranges were derived in-house from testing of 123 healthy control subjects and 
validated with reagent changes.
2.2.3. Simulated thrombin generation—Mathematical simulations of tissue factor 
(TF) initiated thrombin generation were produced as previously described [29–31]. Two 
models were used that initiate coagulation simulation with 5 pM tissue factor (TF); one 
model also includes 1 nM thrombomodulin (TM) to initiate simulation activation of the PC-
negative feedback system (TF + TM Model) [32]. The TF + TM model expands on the TF 
model by including TM binding to thrombin and meizothrombin and the activation of 
protein C (APC) by these complexes [33,34], AT inhibition of thrombin-soluble TM 
complexes, APC cleavage of FVa [31], and assembly and function of partially proteolyzed 
FVa species in prothrombinase [35–38]. For each individual, concentrations of 
procoagulants FII, V, VII, VIII, IX and X and anticoagulants TFPI, AT and PC were 
translated into molar concentrations using literature values for the mean plasma 
concentrations (Supplement3, S3, Table S2); 10% of FVII level is estimated to be in the 
active form for simulations [29,39]. Simulated reactions were solved for thrombin over a 
1200s time frame. Individual profiles were summarized by parameters describing the 
initiation, propagation and termination phases of thrombin generation: maximum level of 
thrombin generation (MaxL), maximum rate of thrombin generated (MaxR), time to 10 nM 
thrombin (clot time, CT), and total thrombin generated (area under the curve, AUC). Results 
for a particular group of individuals were graphically presented as a curve, which represents 
the mean thrombin concentration at each second of the reaction. For carriers with low 
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(≤50%) FIX:C levels, thrombin generation simulations were subsequently conducted with 
increasing FIX:Clevels to simulate medical supplementation with FIX:C to variable target 
levels up to 100% keeping other factors constant. Thrombin generation from the non-Amish 
control (NAC) population was used as a reference point.
2.2.4. Statistical analyses—Data were stored and collated using Microsoft Excel 
(Microsoft, Redmond, WA). Data are reported as the mean with range and/or standard 
deviation. Statistical comparisons were made using student’s t-test, chi-square tests and 
ANOVA with a statistical significance set at p < 0.05 for a two-sided difference. Pearson 
correlation coefficients were calculated between two parameters. SAS statistical software, 
SAS 9.4 by SAS Institute, Inc. was used for all determinations of significance. Non-
parametric statistical comparison of factor levels (specifically those used for simulating 
thrombin generation) across BS value for each subject was not reliable due to the low 
number of subjects with BS > 2. Subjects were subsequently reclassified into one of three 
BS groups: BS = 0, BS = 1–2, or BS = 3+ and analyzed using ANOVA.
3. Results
3.1. Subject characteristics, FIX:C levels and BS
Among post-menarchal females, including 59 carriers and 57 controls, carriers were 
significantly younger than controls (mean age 32 vs. 41) and had lower mean FIX:C level at 
68 (range 19–172) vs. 119 (range 59–196), but the two groups were comparable in total 
mean BS (1.7 and 1.6) and reported bleeding symptoms. A sub-analysis was performed on 
the carriers based on FIX:C level, with 30% (18/59) having factor IX ≤50% (low FIX:C) and 
70% (41/59) having FIX:C > 50% (high FIX:C). The low FIX:C group had a mean FIX:C of 
40 (range 19–50), compared to 80 (range 52–172) in the high FIX:C group. There was no 
significant difference in age, 33y vs. 32y, in the two groups. BS was higher in the low FIX:C 
group, 2.0 vs. 1.6, but the difference was not statistically significant. There was a > 10 fold 
higher frequency of reported dental and minor wound bleeding in carriers with low FIX:C as 
compared to those with high FIX:C. Other bleeding symptoms were comparable (Table 1).
3.1.1. Comparison of other plasma coagulation factor levels—When compared 
to Amish controls, carriers had significantly lower VWF:Ag 108 vs.133 (range 58–219 vs 
59–264) and TAFI, 103 vs. 111 (range 63–117 vs. 69–169).
Fibrinogen, FII, VII, IX, X, XII and PC were significantly lower in the carriers with ≤50% 
vs. > 50% (Table 2). Except for FIX:C other coagulation factors were in the normal reported 
hemostatic range.
3.1.2. BS and factor levels—Subjects were classified into three bleeding score 
categories BS = 0, BS = 1–2, or BS ≥ 3 with an almost equal number of controls and carriers 
in each category (Table 3). An almost equal percentage of carriers (27%) and controls (24%) 
had BS ≥ 3, although the FIX:C level was twofold higher among controls, 129% vs. 54%, in 
this score category. Carriers with BS ≥ 3 had the lowest mean factor IX level 54% compared 
to those with a BS = 0, who had a mean FIX:C of 78%. The only other differences were in 
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PC, which was lower in carriers compared to controls in the BS ≥ 3 category (126% vs 
150%), and FII levels, which were variable in the controls across increasing BS (Table 3).
3.1.3. Thrombin generation kinetics from computational simulations—Plots of 
the mean thrombin generation curves for the carriers and controls are shown in TF Model 
(Fig. 1A) and TF + TM Model (Fig. 1B); mean simulations for the NAC are provided as a 
reference. Carriers were characterized by significantly slower max rates (MaxR) and lower 
max levels (MaxL) of thrombin generation, irrespective of model (Table 4, Fig. 1A, B).
All TG parameters for both models were significantly lower for carriers with low FIX:C 
levels than those with higher (> 50%) FIX:C. The majority of parameters were lower for 
higher FIX:C carriers compared to controls (Table 4). TG curves in the TF model were 
lowest for low FIX:C carriers, while those for higher FIX:CFIX:C:C carriers, controls, and 
NAC almost overlapped (Fig. 1C). TG curves in the TF + TM model were lowest for FIX:C 
carriers ≤ 50%, and successively higher for FIX:CFIX:C:C carriers > 50%, controls, and the 
NAC group (Fig. 1D). MaxL and Max R of TG correlated with FIX:C levels in both carriers 
and controls in both models, with slightly higher correlation coefficients for the TF model 
(Fig. 1E, F,G, H).
The FIX:C carriers with levels > 50% had lower thrombin generation for both models when 
compared to controls, more pronounced for TF + TM model (Fig. 1D).
Correlation plots of thrombin MaxL vs. Factor IX levels for the different populations 
(Carriers – black triangles, Controls – open circles, Non-Amish Controls – grey squares) in 
the (E) TF model, Carriers r = 0.77, Controls r = 0.79; or (F) TF + TM models, Carriers r = 
0.66, Controls r = 0.59. Correlation plots of thrombin MaxR vs. Factor IX levels for the 
different populations (Carriers – black triangles, Controls – open circles, Non-Amish 
Controls – grey squares) in the (G) TF model, Carriers r = 0.77, Controls r = 0.79; or (H) TF 
+ TM models, Carriers r = 0.72, Controls r = 0.81.
3.1.4. Thrombin generation simulation of factor IX replacement—Thrombin 
simulations on the low FIX:C carriers were conducted with a titration of increasing FIX:C 
levels to simulate potential medical intervention, changing only FIX:C levels (60, 80, or 
100%), while keeping all other factor levels of the individual constant. In the TF model, 
these carriers showed a 26–47% increase in MaxL as a group; a full restoration of FIX:C 
levels to mean physiological levels (100%) achieved only 90% of the MaxL achieved in the 
carriers with high FIX:C levels (Fig. 2A). In the TF + TM model, the low FIX:C carriers 
experienced a 41–130% increase based on the FIX:C titration. A restoration of FIX:C levels 
to 80% of mean physiological achieved nearly 85% of the MaxL achieved by the carriers 
with high FIX:C levels. (Fig. 2B).
4. Discussion
Factor levels in hemophilia carriers have been documented to be quite variable within a 
specific hemophilia type and even in those with a unifying pathologic variant [1], largely 
attributed to individual differences in lyonization. Our data in HB carriers show similarly 
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variable FIX:C levels ranging from 19 to 172% with a mean of 68%. Of our postmenarche 
carriers, 30% had levels ≤50%. Historically it is known that females in the mild deficiency 
range, factor levels of 5–50%, are symptomatic with bleeding episodes similar to males with 
mild hemophilia; however, females are also at increased risk of gender-specific bleeding 
events related to the reproductive system. The decision to provide clotting factor 
replacement/hemostatic therapy to a carrier based upon a specific level is not entirely 
elucidated, and real world practice varies widely. The prediction of bleeding risk in carriers 
based upon levels alone has been confounded by reports of abnormal bleeding symptoms 
reported in carrier females of FVIII deficiency whose levels are above 40% or within the 
normal range [10]. Bleeding scores like MCMDM-1, Self-BAT (bleeding assessment tool), 
and ISTH BAT have been evaluated as a surrogate marker for prediction of bleeding events 
in a variety of populations including hemophilia [9–11].
In this report, an in-house bleeding questionnaire and scoring system were utilized. The 
standard BAT underestimates the bleeding potential in this population, because higher scores 
are assigned for medical care and interventions, which the Amish are less likely to seek [40]. 
Our finding of BS < 2 in all participants is in contrast to other studies which have shown a 
higher BS ≥ 3 using different BATs in HB carriers [7,11]. This is possibly due to the lack of 
reporting bleeding symptoms in the Amish owing to their stoic nature and hesitation in 
seeking medical care compared to other populations [40]. The only significant finding was 
in BS categories and FIX:C levels, showing an inverse relation with BS ≥ 3 having the 
lowest FIX:C levels, although correlation between factor IX:C levels and BS has not been 
consistently seen in other studies [7].
Although it was expected that reproductive tract bleeding would be higher in carriers as 
compared to controls, this was not seen in our cohort (menstrual bleeding 5% vs 12%, p = 
0.17; PPH 32% vs 30%, p = 0.78 respectively). Previously, a significantly higher frequency 
of these bleeding symptoms was reported for HB carriers compared to controls (menstrual 
bleeding 47% vs 15%, p < 0.01; PPH 47% vs 9%, p < 0.01) although this report included a 
smaller sample size of 19 women with a lower range of FIX:C at 27–81%, mean of 54% [7]. 
Only 3% (2/59, with 54% and 79% FIX:C) of our carriers reported joint bleeds (one knee 
and 3 ankle), which was not significantly higher than controls. Details about the mechanism 
of hemarthrosis were not captured through our questionnaire. In other studies of HB carriers, 
slightly higher hemarthrosis frequencies have been observed at 5–8% [7,8]. Even in the 
subgroup analysis of carriers by FIX:C level, reproductive bleeding symptoms and 
hemarthrosis were not significantly higher in the low FIX:C level group; however they had a 
> 10 fold higher frequency of reported dental and minor wound bleeding. This finding 
should be interpreted with caution as the Amish have a higher prevalence of poor oral 
hygiene, which could increase the rate of oral bleeding observed when FIX:C levels are 
decreased and gingivitis is present. In addition, women actively participate in physically 
demanding chores which could increase the incidence of minor wounds [40]. The similarity 
in BS between carriers and controls could also be due to the age difference between the 
groups, with the younger carriers less likely to have experienced some types of bleeding, 
such as post-partum hemorrhage, despite having lower FIX:C levels.
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This study presents the first report of an extensive coagulation profile in HB carriers. This 
was done with the two-fold intention of assessing the impact of all procoagulants and 
anticoagulants on bleeding scores and to create mathematical thrombin generation models 
for carriers and controls. There was no significant impact of these coagulation factor levels 
on the total BS. Apart from significant differences in FIX:C only levels of VWF:Ag and 
TAFI were lower in carriers which did not translate into a higher mean BS in carriers. The 
subgroup analysis of carriers above and below 50% demonstrated several factors which were 
lower in the FIX:C > 50% group (I, II, VII, IX, X, XII and PC), although this difference did 
not impact the BS between the two groups possibly because both anticoagulants and 
procoagulants were lower balancing out the effect. Although extended coagulograms have 
been reported in FVIII carriers [10,13], this is the first report, to our knowledge, in HB 
carriers. There was a significant lower FIX:C in carriers with BS ≥ 3 vs. those with BS = 0, 
indicating that FIX:C levels do have a negative correlation with bleeding symptoms. Also of 
note, was the unexpected lower PC in carriers vs. controls in the BS ≥ 3 category. PC levels 
needs to be further studied in a larger sample size of FIX:C carriers to see if the difference 
persists. Vitamin K deficiency fails to explain the difference in the PC levels in carriers and 
controls as other Vitamin K dependent proteins FII and FVII were not significantly different.
Global hemostatic assays, including thrombin generation assay (TGA) and 
thromboelastogram (TEG), have gained increased attention for their use in evaluation of 
patients’ bleeding disorders and response to a variety of therapies. TGA is performed in 
plasma samples, which has practical application for use in stored samples. TGA assays may 
have utility in hemophilia carriers with a range of FVIII or IX levels and variation in 
bleeding symptoms to increase understanding of the impact of other procoagulants and/or 
anticoagulants on the bleeding phenotype [12]. Although TGA has several advantages 
including easy to perform, commercially available, widely accepted by hematologists and 
lastly easy interpretation; a disadvantage of TGA is the lack of standardization. In our 
research study, the complex reaction pathway of thrombin formation/inhibition is 
approximated by the theoretical curves generated by computer modeling which has the 
capacity to anticipate the presence of minute concentrations of reactants and enzymes. 
Carriers with ≤50% FIX:C had the lowest TG parameters and curves; and, interestingly, 
carriers with levels > 50% had significantly lower TG parameters and curves than all 
controls (Amish and non-Amish) in the TF + TM model, implying that the carriers > 50% 
might have a higher tendency to bleed as compared to the normal population; this should be 
further substantiated with real-time global hemostatic assays in a larger set of cases and 
controls. Using our mathematical models we were able to simulate the effect of factor 
replacement therapy in those individuals with a mild FIX:C deficiency. The TF + TM model 
was most responsive to increasing FIX:C levels, an increase to 80% of mean physiological 
was sufficient to generate an average profile similar to the HB carriers with levels of FIX:C 
> 50%. This model captured more of the differences between the carriers based on FIX:C 
levels, most notably the lower levels of PC in those with FIX:C ≤ 50%. Whether these lower 
PC levels concurrent with lower FIX:C levels are the result of a compensatory mechanism is 
unknown and may be worthy of future investigation.
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4.1. Limitations
We used an in-house bleeding questionnaire only applied in this population, without a 
validated cut off for a significant bleeding score in women. It is possible that a low score of 
1 could be significant in this population; this requires further evaluation with a larger 
number of subjects in this population for validation. Our Amish controls were not age 
matched which could result in differences in some coagulation factor levels such as FVIII 
and VWF:Ag which are known to vary with age; however FIX:C is not known to be 
affected. The age difference might also affect BS. A cross sectional survey for bleeding 
symptoms with recall bias in a stoic population could have influenced the reported bleeding 
symptoms in our study. The results of this study are not generalizable to other FIX:C carriers 
with other genetic defects as we were limited by a homogenous population with a unifying 
mutation. Additionally, there are no other reports of the bleeding phenotype in female 
heterozygous carriers of this specific variant for comparison to our cohort. Although an 
extensive coagulogram was performed, VWF Ristocetin, blood group, platelet count and 
platelet function, which could influence bleeding scores, could not be performed due to lack 
of funding. The mathematical modeling for thrombin generation does not replace a 
commercially available thrombin generation assay which is a validated and universal 
standardized tool for evaluating the coagulation system. The mathematical models are a 
unique way of analyzing thrombin generation in a research setting and allow us to simulate 
different scenarios (as was performed with FIX:C levels restoration to physiological values, 
Fig. 2A, B) to look at possible outcomes. It would be ideal to look at actual thrombin 
generation assay along with the mathematical model for correlation and this is the next step 
of our project for the 99 FIX:C carrier samples at our center.
5. Conclusion
This research study is the first to use BS, extensive coagulation factor testing, and detailed 
mathematical models for thrombin generation in genetically similar population of HB 
carriers and controls. These data support the concept that, overall, carriers of hemophilia B 
with either low or normal/high FIX:C levels have a significant difference in thrombin 
generation compared to controls; whether or not this translates into an actual difference in 
bleeding phenotype will need to be analyzed in a larger sample size across variable FIX:C 
levels. Mathematical models of thrombin generation are a novel way of analyzing the 
hemostatic milieu and would need further validation in hemophilia carriers to assess their 
clinical utility along with extensive correlation with actual thrombin generation assays.
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Fig. 1. 
Thrombin simulation of Amish cohorts. Computational simulations of carriers (solid black 
line) and controls (dotted black line) in response to (A) 5 pM TF or (B) 5 pM TF and 1 nM 
soluble Thrombomodulin. Curves are the Mean + SEM of all individual curves. Simulation 
of NAC (Non-Amish Controls) (dashed grey line) is provided as a reference. Carriers are 
then divided based on Factor IX Level ≤50% (dashed black) or > 50% (solid black) and 
thrombin generation curves in response to (C) 5 pM TF or (D) 5 pM TF and 1 nM soluble 
Thrombomodulin; Controls and NAC are shown as reference.
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Fig. 2. 
Simulated effects of factor IX supplementation. Thrombin simulations using the (A) TF only 
or (B) TF + TM model were conducted on the post-menarchal Carriers, mean curves were 
generated based on high (> 50%, solid black line) or low (≤50%, dashed black line) 
FIX:Clevels. Simulations on low FIX:C Carriers were conducted with a titration of 
increasing FIX:C levels: 60% (dot+dash grey line), 80% (dash grey line) and 100% (solid 
grey line).
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Table 1
Subject characterization by FIX:C level, bleeding score (BS) and bleeding symptoms in Amish hemophilia B 
carriers and controls.
Carriers (N = 59)
Mean (SD)
Controls (N = 57)
Mean (SD)
p Carriers
FIX:C ≤50% (N = 18/59)
Mean (SD)
Carriers
FIX:C > 50% (N = 41/59)
Mean (SD)
p
Age in years 32.3 (14.5) 40.7 (16.2) < 0.05 33.2 (14.0) 31.9 (14.9) 0.76
Total BS 1.71 (2.04) 1.61 (2.09) 0.80 2.06 (1.98) 1.56 (2.07) 0.40
FIX:Ca % 67.9 (30.0) 118.8 (29.3) < 0.05 40.0 (9.3) 80.1 (27.6) < 0.05
%b %b p %b %b p
Bruising 30.5 31.6 0.90 22.2 34.2 0.36
Epistaxis 8.5 8.8 0.95 5.6 9.8 0.59
Dental bleeding 8.5 5.3 0.50 22.2 2.4 < 0.05
Surgical bleeding 6.8 10.5 0.47 11.1 4.9 0.38
Menorrhagia 5.1 12.3 0.17 5.6 4.9 0.91
PPHc 32.2 29.8 0.78 33.3 31.7 0.90
Hemarthrosis 3.4 0.0 0.16 0.0 4.9 0.34
Wound bleeding 3.4 1.8 0.58 11.1 0.0 < 0.05
a
FIX:C level carriers vs. controls-range 19–172 vs. 59–196.
b% of subjects from the group with BS of 1 or above.
c
PPH: post-partum hemorrhage.
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Table 2
Mean coagulation factor levels of Amish hemophilia B carriers and controls.
Measure Carriersa (N-59)
Mean (SD)
Controls (N-57)
Mean (SD)
P Carriersb
IX:C ≤ 50% (N-18/59)
Mean (SD)
Carriers
IX:C > 50% (N-41/59)
Mean (SD)
p
Factor XI, % 126.0 (29.2) 129.8 (31.8) 0.51 124.3 (26.2) 126.7 (30.7) 0.77
Factor XII, % 154.3 (51.4) 148.5 (44.6) 0.52 125.4 (44.9) 166.9 (49.3) < 0.05
Fibrinogen, g/L 3.44 (0.75) 3.65 (0.7) 0.13 3.10 (0.72) 3.60 (0.71) < 0.05
VWF:Ag, % 107.8 (30.8) 132.9 (49.2) < 0.05 108.2 (26.5) 107.7 (32.8) 0.95
TAFI, % 102.6 (19.7) 111.1 (24.8) < 0.05 96.4 (12.2) 105.2 (21.8) 0.12
Factors (%) used for modeling thrombin kinetics
Factor II 121.2 (21.4) 119.3 (16.5) 0.59 112.9 (18.7) 124.8 (21.7) < 0.05
Factor V 104.1 (22.3) 107.6 (20.1) 0.37 105.4 (32.7) 103.5 (16.3) 0.76
Factor VII 115.1 (28.0) 124.9 (34.4) 0.09 103.3 (24.0) 120.2 (28.3) < 0.05
Factor VIII 142.3 (47.3) 157.5 (52.7) 0.11 137.3 (43.1) 144.6 (49.3) 0.59
Factor IX:C 67.9 (30.0) 118.8 (29.3) < 0.05 40.0 (9.3) 80.1 (27.6) < 0.05
Factor X 108.9 (21.0) 110.4 (22.4) 0.71 100.7 (18.9) 112.6 (21.0) < 0.05
AT 117.0 (15.9) 117.7 (14.6) 0.81 120.8 (16.6) 115.3 (15.5) 0.22
Protein C 132.9 (27.9) 137.2 (31.0) 0.44 121.4 (27.1) 137.9 (27.1) < 0.05
TFPITotal 64.6 (18.1) 68.6 (17.5) 0.23 68.8 (19.6) 62.8 (17.4) 0.24
a
HB carriers vs. controls-range 19–172 vs. 59–196.
b
HB carriers ≤50% vs. > 50%-range 19–50 vs. 52–172.
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Table 3
Mean factor levels by bleeding score category.
Measure Cohort BS = 0 BS = 1–2 BS ≥ 3 p
N Carrier 22 21 16
Control 22 21 14
Factor II Carrier 126.0 ± 24.9 114.2 ± 11.8 123.8 ± 24.6 0.17
Control 120.3 ± 14.4 112.4 ± 13.8 127.9 ± 19.8 < 0.05
Factor V Carrier 99.3 ± 14.7 103.8 ± 29.5 110.9 ± 19.5 0.29
Control 102.8 ± 19.4 108.6 ± 17.3 113.6 ± 24.5 0.29
Factor VII Carrier 117.3 ± 24.6 108.8 ± 34.5 120.3 ± 22.2 0.43
Control 123.4 ± 43.4 121.9 ± 30.1 131.6 ± 24.2 0.70
Factor VIII Carrier 148.5 ± 39.7 141.5 ± 57.4 135.0 ± 43.8 0.69
Control 157.7 ± 56.7 166.0 ± 53.0 144.3 ± 46.1 0.50
Factor IX:C Carrier 78.5 ± 32.9* 67.0 ± 32.0* 54.4 ± 15.6*, + < 0.05
Control 120.2 ± 28.3 110.9 ± 28.8 128.7 ± 30.2 0.20
Factor X Carrier 109.7 ± 20.2 112.5 ± 23.3 103.2 ± 18.8 0.40
Control 115.7 ± 25.1 101.6 ± 20.3 115.4 ± 17.5 0.07
AT Carrier 112.9 ± 17.4 118.3 ± 15.0 120.9 ± 14.4 0.28
Control 117.8 ± 14.9 113.8 ± 13.2 123.2 ± 15.3 0.18
Protein C Carrier 141.4 ± 28.9 129.4 ± 27.5 125.8 ± 25.8* 0.18
Control 136.5 ± 34.2 129.3 ± 31.2 150.0 ± 21.5 0.15
TFPITotal Carrier 60.6 ± 13.6 63.1 ± 16.0 72.1 ± 24.2 0.14
Control 67.8 ± 14.6 71.5 ± 20.6 65.5 ± 17.1 0.60
*
Indicates p < 0.05 for comparison of carrier and control in the same BS category.
+
Indicates p < 0.05 in comparison of BS = 0 vs. BS ≥3 for Carriers.
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Table 4
Thrombin generation parameters in hemophilia B carriers and controls.
Model Measure Carriers Controls Carriers
FIX:C ≤ 50%
Carriers
FIX:C > 50%
N 59 57 18 41
TF model mean CT (s) 146.3 146.3 169.0** 136.4
MaxL,(nM) 372.2* 426.5 278.7** 413.2
MaxR (nM/s) 2.5* 3.6 1.56** 2.96t
AUC (nM•s) 85,785 81,498 74,787** 90,613t
TF + TM model mean CT(s) 291.8 284.8 331.8** 277.2
MaxL (nM) 69.4* 115.3 38.6** 82.9t
MaxR (nM/s) 0.44* 0.81 0.21** 0.54t
AUC (nM•s) 18,862* 30,713 10,758** 22,420t
*
Indicates p < 0.05 between Carriers and Controls.
**
Indicates p < 0.05 between Carriers with FIX:C ≤ 50% and FIX:C > 50%.
t
Indicates p < 0.05 between Controls and Carriers with FIX:C > 50%.
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